Nephro-Urology Monthly

Published by: Kowsar

Association of the Serum Vascular Endothelial Growth Factor Levels With Benign Prostate Hyperplasia and Prostate Malignancies

Mohammad Reza Sharif 1 , Amirreza Shaabani 2 , Hossein Mahmoudi 2 , Hassan Nikoueinejad 3 , * , Hossein Akbari 4 and Behzad Einollahi 3
Authors Information
1 Department of Pediatrics, Kashan University of Medical Sciences, Kashan, IR Iran
2 Department of Urology, Kashan University of Medical Sciences, Kashan, IR Iran
3 Department of Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
4 Department of Biostatistics, Kashan University of Medical Sciences, Kashan, IR Iran
Article information
  • Nephro-Urology Monthly: May 01, 2014, 6 (3); e14778
  • Published Online: April 27, 2014
  • Article Type: Research Article
  • Received: September 11, 2013
  • Revised: November 11, 2013
  • Accepted: March 15, 2014
  • DOI: 10.5812/numonthly.14778

To Cite: Sharif M R, Shaabani A, Mahmoudi H, Nikoueinejad H, Akbari H, et al. Association of the Serum Vascular Endothelial Growth Factor Levels With Benign Prostate Hyperplasia and Prostate Malignancies, Nephro-Urol Mon. 2014 ; 6(3):e14778. doi: 10.5812/numonthly.14778.

Abstract
Copyright © 2014, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Miotto A, Jr., Srougi M, Brito GA, Leite KM, Nesrallah AJ, Ortiz V. Value of various PSA parameters for diagnosing prostate cancer in men with normal digital rectal examination. Int Braz J Urol. 2004; 30(2): 109-13[PubMed]
  • 2. Chakravarti A, Zhai GG. Molecular and genetic prognostic factors of prostate cancer. World J Urol. 2003; 21(4): 265-74[DOI][PubMed]
  • 3. Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol. 2004; 22(9): 1655-63[DOI][PubMed]
  • 4. Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol. 1997; 157(6): 2323-8[PubMed]
  • 5. Green MM, Hiley CT, Shanks JH, Bottomley IC, West CM, Cowan RA, et al. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys. 2007; 67(1): 84-90[DOI][PubMed]
  • 6. Translational Research: the Role of VEGF in Tumor Angiogenesis. Proceedings of a symposium. Washington, DC, USA. November 16, 1999. Oncologist. 2000; 5 Suppl 1: 1-57[PubMed]
  • 7. Duque JL, Loughlin KR, Adam RM, Kantoff P, Mazzucchi E, Freeman MR. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics (Sao Paulo). 2006; 61(5): 401-8[PubMed]
  • 8. Peyromaure M, Badoual C, Camparo P, Grabar S, Goulvestre C, Fulla Y, et al. Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer. Oncol Rep. 2007; 18(1): 145-9[PubMed]
  • 9. Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I. Urinary levels of vascular endothelial growth factor in patients with prostate cancer as a predictor of disease progression. Anticancer Res. 2005; 25(5): 3645-9[PubMed]
  • 10. Peyromaure M, Camparo P, Badoual C, Descazeaud A, Dinh-Xuan AT. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy. BJU Int. 2007; 99(5): 1150-3[DOI][PubMed]
  • 11. Yang J, Wu HF, Qian LX, Zhang W, Hua LX, Yu ML, et al. Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression. Asian J Androl. 2006; 8(2): 169-75[DOI][PubMed]
  • 12. Latil A, Bieche I, Pesche S, Valeri A, Fournier G, Cussenot O, et al. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer. 2000; 89(2): 167-71[PubMed]
  • 13. Kaushal V, Mukunyadzi P, Dennis RA, Siegel ER, Johnson DE, Kohli M. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res. 2005; 11(2 Pt 1): 584-93[PubMed]
  • 14. Delongchamps NB, Peyromaure M. The role of vascular endothelial growth factor in kidney and prostate cancer. Can J Urol. 2007; 14(5): 3669-77[PubMed]
  • 15. Soulitzis N, Karyotis I, Delakas D, Spandidos DA. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol. 2006; 29(2): 305-14[PubMed]
  • 16. Walsh K, Sherwood RA, Dew TK, Mulvin D. Angiogenic peptides in prostatic disease. BJU Int. 1999; 84(9): 1081-3[PubMed]
  • 17. Mao K, Badoual C, Camparo P, Delongchamps NB, Vieillefond A, Dinh-Xuan AT, et al. The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy. Can J Urol. 2008; 15(5): 4257-62[PubMed]
  • 18. Madu CO, Lu Y. Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010; 1: 150-77[PubMed]
  • 19. Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Bicknell R, et al. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int. 2000; 85(3): 276-80[PubMed]
  • 20. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350(22): 2239-46[DOI][PubMed]
  • 21. Sutcliffe P, Hummel S, Simpson E, Young T, Rees A, Wilkinson A, et al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technol Assess. 2009; 13(5)-219[DOI][PubMed]
  • 22. Pan L, Baek S, Edmonds PR, Roach M, 3rd, Wolkov H, Shah S, et al. Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610. Radiat Oncol. 2013; 8: 100[DOI][PubMed]
  • 23. Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Ann Intern Med. 2009; 150(9): 595-603[PubMed]
  • 24. VanCleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN, et al. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate. 2010; 70(4): 341-52[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments